Csl112 drug
WebCSL112 (apolipoprotein A-I [apoA-I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC). WebCSL112 is a novel formulation of human apoA-I. The apoA-I is reconstituted with phosphatidylcholine to form disc-shaped HDL particles, each bearing 2 molecules of human apoA-I and 110 molecules of phosphatidyl-choline.22 CSL112 preparations contain sucrose as a stabilizing agent. In ex vivo studies, CSL112 was an efficient
Csl112 drug
Did you know?
WebFeb 1, 2024 · The SPECL anti-CSL112 and anti-apoA-I assays were highly specific, as demonstrated by the reduction of signal from the addition of the respective drug after the sample pre-treatment (Fig. 3). As shown in Fig. 4 , the addition of either 100 and 500 μg/mL of CSL112 ( Fig. 4 A) or apoA-I ( Fig. 4 B) resulted in a >90% reduction of signal at all ... WebAug 7, 2024 · CSL112 or placebo was administered as a single 2 h i.v. infusion into a suitable peripheral or central vein. Pharmacokinetics and pharmacodynamics of apoA-I ApoA-I concentration was assessed by an immunonephelometric method run on Roche Modular P at a specialty lipid laboratory (Pacific Biomarkers).
WebCSL112 may offer a new approach for rapidly stabilizing atherosclerotic plaque lesions and is being developed for reduction in the risk of early cardiovascular … WebMar 26, 2024 · “CSL112 is an exciting new approach in cardiovascular medicine that may help protect our patients when they are most vulnerable.” Research showed that …
WebThe CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Am Heart J. 2024 Feb;208:81-90. doi: 10.1016/j.ahj.2024.11.008. Epub 2024 Nov 22. WebSep 21, 2024 · CSL112 (Apolipoprotein A-I [human]) is a novel formulation of intravenous plasma-derived apolipoprotein A-I (apoA-I) formulated with phosphatidylcholine (PC) and stabilized with sucrose. ... were noted, with no signs of drug-related renal toxicity detected. Furthermore, a recent phase 2b study of 4 weekly doses of CSL112 in subjects with AMI ...
WebThis is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment …
WebJan 14, 2024 · CSL 112 - AdisInsight Drug Profile CSL 112 Alternative Names: ApoA-1; Apolipoprotein A-I - CSL Behring; CSL-112; CSL112 (reconstituted HDL) - CSL; CSL112 apo-AI; rHDL - CSL Latest Information Update: 14 Jan 2024 Price : $50 * Buy Profile Adis is an information provider. We do not sell or distribute actual drugs. douglas hyde and the gaelic leagueWebMar 16, 2024 · During the last decade, CSL112 has been extensively studied in Phase 1 and 2 trials and has shown promising results. In particular, CSL112 has been studied in the Phase 2b AEGIS trial... douglas hydrating face maskWebOct 25, 2024 · CSL112 is an investigational drug containing human purified apoA-I, formulated with phosphatidylcholine (PC) and stabilized with sucrose. 35 CSL112 is supplied sterile and lyophilized in an evacuated vial, and was reconstituted with 50 mL of water for injection and administered intravenously at doses of 2 g (1 vial) or 6 g (3 vials) over 2 ... douglas immigration officedouglas inchWebCSL112 is a reconstituted, infusible human plasma-derived apolipoprotein A-I (apoA-I) that increases cholesterol efflux capacity – an ex vivo measure of the ability of HDL to accept cholesterol from macrophages. Areas covered: This article reviews the pharmacology of CSL112 and its current clinical development status. civil air patrol branding portalWebCSL112 is a reconstituted HDL (rHDL) particle composed of native ApoA1 purified from human plasma and phosphatidylcholine that can be intravenously infused. It is a … civil air patrol book 1WebNov 5, 2024 · CSL112, Apolipoprotein A-I (Human), is a novel formulation of human plasma-derived apoA-I, the primary functional component of high-density lipoproteins (HDL). Studies have shown that an infusion... civil air patrol board of governors